October 7, 2025 — Leads & Copy — Allurion Technologies, Inc. (NYSE: ALUR) has announced the publication of a peer-reviewed study on the consecutive use of the Allurion Smart Capsule, a swallowable weight-loss device. The study, published in Obesity Surgery, showed that two consecutive treatments resulted in an average total body weight loss of 22.1% (19.3 kg), comparable to bariatric surgery and high-dose GLP-1 therapy.
The multicenter, retrospective study included 121 overweight and obese adults across 11 international sites, with no serious device-related adverse events reported.
Dr. Roberta Ienca, the study’s Senior Author and Medical Doctor at Nuova Villa Claudia Clinic in Rome, Italy, stated that the study provides evidence that consecutive use of the Allurion Smart Capsule is safe and effective. She added that it shows patients can achieve weight loss of over 20% without surgery, making it a flexible tool for patients at different stages of their weight-loss journey.
The study design mirrors the approach used in AUDACITY, the company’s FDA pivotal study. Based on the results of the AUDACITY trial, Allurion submitted the fourth and final module of the Pre-Market Approval (PMA) application to the FDA earlier this year.
Dr. Shantanu Gaur, Founder and CEO of Allurion, stated that the data show that a non-surgical, swallowable device can deliver weight-loss outcomes once thought possible only with surgery or high-dose drugs, and that the company’s goal is to redefine what is possible in non-surgical weight loss and set a new benchmark for innovation in the field.
The Allurion Smart Capsule is designed to be swallowed during a brief outpatient visit, filled once in the stomach, and pass naturally after four months. When combined with Allurion’s Virtual Care Suite, patients also receive digital support and remote monitoring.
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.
Source: Allurion
